Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AQX-1125 misses the mark in COPD trial
September 2015
SHARING OPTIONS:

VANCOUVER, British Columbia—Clinical-stage pharmaceutical company Aquinox Pharmaceuticals Inc. is shifting gears on AQX-1125 after the drug candidate failed to demonstrate efficacy in its Phase 2 FLAGSHIP clinical trial in chronic obstructive pulmonary disease (COPD) patients with a history of frequent exacerbations. Patients who received 200 mg orally once daily for 12 weeks saw no difference in COPD symptoms compared to placebo, and no benefit was observed with regards to the secondary endpoint of medically treated exacerbations, either. AQX-1125 was shown to be well tolerated, however, and David Main, president and CEO of Aquinox, noted that “Given the encouraging activity seen in our recent LEADERSHIP trial, our focus will be on the further development of AQX-1125 in bladder pain syndrome/interstitial cystitis. In addition, we are awaiting results from our KINSHIP trial in atopic dermatitis.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.